China Medical System Holdings Ltd (CMS), a subsidiary of Treasure Sea Ltd, is a pharmaceutical company that markets, promotes and sells pharmaceutical drugs. Its offering product includes plendil, deanxit, xinhuosu, ursofalk, bio flor, combizym, hirudoid, aethoxysklerol, lansoprazole enteric, tacrolimus, cyclosporine, paliperidone, latanoprost, levetiracetam, pons, extendedrelease and doxorubicin hydrochloride liposome, among others. CMS medical aesthetic product comprises vmonalisa, stratamark, mesenteric-mesohyl, and neauvia hyaluronic series. It also offer clinical development services. The company's product pipeline provides various therapeutic fields which include the nervous system, ophthalmology, dermatology, endocrine system, oncology, nephrology, immune system, digestive system and anti-infection. CMS is headquartered in Hong Kong.
China Medical System Holdings Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Complex Generic: | Stratamark |
Doxorubicin Hydrochloride Liposome Injection | |
Paliperidone Extended-Release Tablets | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, CMS Skinhealth entered into a partnership with Incyte Corp for the advancement and commercialization of povorcitinib. |
2024 | Others | In April, the company's New Drug Application was accepted by the National Medical Products Administration of China for Desidustat Tablets. |
2024 | Regulatory Approval | In March, the company secured approval from the National Medical Products Administration of the People’s Republic of China to commence a clinical trial of ruxolitinib cream for the treatment of mild to moderate atopic dermatitis. |
Competitor Comparison
Key Parameters | China Medical System Holdings Ltd | Tasly Pharmaceutical Group Co Ltd | Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | Hubei Guangji Pharmaceutical Co Ltd | Beijing Beilu Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | Hong Kong | China | China | China | China |
City | Hong Kong | Tianjin | Tianjin | Huanggang | Beijing |
State/Province | Guangdong | Tianjin | Tianjin | Hubei | Beijing |
No. of Employees | 5,701 | 9,223 | 4,619 | 1,256 | 923 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Lam Kong | President; Chief Executive; Chairman | Executive Board | 2006 | 58 |
Chen Yanling | Vice President; Chief Financial Officer; Director | Executive Board | 2006 | 52 |
Chen Hongbing | Vice President; Chief Operating Officer; Director | Executive Board | 2006 | 56 |
Ma Liey | General Manager - Business Operations Center | Senior Management | - | 53 |
Peng Huaizheng | Chief Business Officer | Senior Management | - | 61 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer